| Literature DB >> 26830082 |
Yuma Tega1, Chihiro Yuzurihara2, Yoshiyuki Kubo3, Shin-Ichi Akanuma4, Carsten Ehrhardt5, Ken-Ichi Hosoya6.
Abstract
Nicotine is a potent addictive alkaloid, and is rapidly absorbed through the alveoli of the lung. However, the transport mechanism of nicotine at the human alveolar epithelial barrier has not been investigated in great detail. In the present study, the transport mechanism of nicotine across alveolar epithelium was investigated in vitro using A549 cells, a human adenocarcinoma-derived cell line with an alveolar epithelial cell like phenotype. Nicotine uptake by A549 cells exhibited time-, temperature-, and concentration-dependence with a Km of 50.4 μM. These results suggest that a carrier-mediated transport process is involved in nicotine transport in human alveolar epithelial cells. Nicotine uptake by A549 cells was insensitive to change in extracellular pH. Moreover, nicotine uptake by A549 cells could be inhibited by organic cations such as verapamil and pyrilamine, but not typical substrates of organic cation transporters and β2-agonist. These results suggest that a novel, not yet molecularly identified, organic cation transporter plays a role in nicotine transport which is unlikely to interact with β2-agonist transport. This nicotine influx transporter in human alveolar epithelium might have implications for the rapid absorption of nicotine into the systemic circulation.Entities:
Keywords: Bronchodilator; Drug transport; Inhalation biopharmaceutics; Nicotine; Pulmonary drug disposition; Respiratory epithelium
Mesh:
Substances:
Year: 2015 PMID: 26830082 DOI: 10.1016/j.dmpk.2015.11.006
Source DB: PubMed Journal: Drug Metab Pharmacokinet ISSN: 1347-4367 Impact factor: 3.614